Moderna, Inc.
MRNAModerna, Inc. (/məˈdɜːrnə/ mə-DUR-nə) is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".
Drugs in Pipeline
41
Phase 3 Programs
16
Upcoming Catalysts
12
Next Catalyst
Apr 14, 2026
17dMarket Overview
Stock performance and key metrics
12 upcoming, 0 past
mRNA-1283
COVID-19
mRNA-1010
Seasonal Influenza
mRNA-4157
Personalized Cancer Vaccine
Melanoma
Fluarix Tetra
Seasonal Influenza
mRNA-1403
Acute Gastroenteritis
mRNA-1273.214
SARS-CoV-2
mRNA-1083
COVID-19
mRNA-1345
Respiratory Syncytial Virus
mRNA-1273
SARS-CoV-2
Influenza Vaccine
SARS-CoV-2
Fluarix®
Seasonal Influenza
Investigational mRNA-1273.815
SARS-CoV-2
Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine
Seasonal Influenza
mRNA-1283.222
COVID-19
mRNA-1273.211
SARS-CoV-2
Fluzone HD
Respiratory Syncytial Virus
mRNA-1405
Norovirus Acute Gastroenteritis
Biological: mRNA-1273
SARS-CoV-2
mRNA-1073
SARS-CoV-2
mRNA-2808
Relapsed or Refractory Multiple Myeloma
mRNA-1189
Epstein-Barr Virus Infection
mRNA-1283.211
SARS-CoV-2
Active Comparator
Seasonal Influenza
mRNA-1468
Herpes Zoster
mRNA-1893
Zika Virus
mRNA-1975
Lyme Disease
mRNA-1083 Composition 1 Dose A Lot A
Influenza
mRNA-3705
Methylmalonic Acidemia
mRNA-3745
Glycogen Storage Disease
mRNA-1010.4
Influenza
Influenza Vaccine 1
SARS-CoV-2
Pembrolizumab
Advanced Solid Tumors
Egg-based Quadrivalent Influenza Vaccine
Influenza
mRNA-1195
Multiple Sclerosis
mRNA-1647
Cytomegalovirus Infection
mRNA-1030
Seasonal Influenza
mRNA-1769
Smallpox
mRNA-1608
Genital Herpes
mRNA-1018 for H5N8
Influenza
mRNA-1011.1
Seasonal Influenza
mRNA-3927
Propionic Acidemia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
mRNA-1283 | Phase 3 | COVID-19 | Fast Track | - |
mRNA-1010 | Phase 3 | Seasonal Influenza | Fast Track | - |
mRNA-4157 Personalized Cancer Vaccine | Phase 3 | Melanoma | OrphanFast TrackBreakthrough | - |
Fluarix Tetra | Phase 3 | Seasonal Influenza | - | - |
mRNA-1403 | Phase 3 | Acute Gastroenteritis | - | - |
mRNA-1273.214 | Phase 3 | SARS-CoV-2 | - | - |
mRNA-1083 | Phase 3 | COVID-19 | - | - |
mRNA-1345 | Phase 3 | Respiratory Syncytial Virus | - | - |
mRNA-1273 | Phase 3 | SARS-CoV-2 | - | - |
Influenza Vaccine | Phase 3 | SARS-CoV-2 | - | - |
Fluarix® | Phase 3 | Seasonal Influenza | - | - |
Investigational mRNA-1273.815 | Phase 3 | SARS-CoV-2 | - | - |
Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine | Phase 3 | Seasonal Influenza | - | - |
mRNA-1283.222 | Phase 3 | COVID-19 | - | - |
mRNA-1273.211 | Phase 3 | SARS-CoV-2 | - | - |
Fluzone HD | Phase 3 | Respiratory Syncytial Virus | - | - |
mRNA-1405 | Phase 2 | Norovirus Acute Gastroenteritis | - | - |
Biological: mRNA-1273 | Phase 2 | SARS-CoV-2 | - | - |
mRNA-1073 | Phase 2 | SARS-CoV-2 | - | - |
mRNA-2808 | Phase 2 | Relapsed or Refractory Multiple Myeloma | - | - |
mRNA-1189 | Phase 2 | Epstein-Barr Virus Infection | - | - |
mRNA-1283.211 | Phase 2 | SARS-CoV-2 | - | - |
Active Comparator | Phase 2 | Seasonal Influenza | - | - |
mRNA-1468 | Phase 2 | Herpes Zoster | - | - |
mRNA-1893 | Phase 2 | Zika Virus | - | - |
mRNA-1975 | Phase 2 | Lyme Disease | - | - |
mRNA-1083 Composition 1 Dose A Lot A | Phase 2 | Influenza | - | - |
mRNA-3705 | Phase 2 | Methylmalonic Acidemia | - | - |
mRNA-3745 | Phase 2 | Glycogen Storage Disease | - | - |
mRNA-1010.4 | Phase 2 | Influenza | - | - |
Influenza Vaccine 1 | Phase 2 | SARS-CoV-2 | - | - |
Pembrolizumab | Phase 2 | Advanced Solid Tumors | - | - |
Egg-based Quadrivalent Influenza Vaccine | Phase 2 | Influenza | - | - |
mRNA-1195 | Phase 2 | Multiple Sclerosis | - | - |
mRNA-1647 | Phase 2 | Cytomegalovirus Infection | - | - |
mRNA-1030 | Phase 2 | Seasonal Influenza | - | - |
mRNA-1769 | Phase 2 | Smallpox | - | - |
mRNA-1608 | Phase 2 | Genital Herpes | - | - |
mRNA-1018 for H5N8 | Phase 2 | Influenza | - | - |
mRNA-1011.1 | Phase 2 | Seasonal Influenza | - | - |
mRNA-3927 | Phase 2 | Propionic Acidemia | - | - |
COVID-19
1 drug in this indication
Seasonal Influenza
1 drug in this indication
Melanoma
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)